4801-80-3

Basic information

• Product Name: Z-PHE-NH2
• Synonyms: N-ALPHA-CBZ-L-PHENYLALANINE AMIDE;N-ALPHA-CARBOBENZOXY-L-PHENYLALANINE AMIDE;Z-L-PHENYLALANINE AMIDE;Z-PHENYLALANINE-NH2;Z-PHE-NH2;N-alpha-Benzyloxycarbonyl-L-phenylalanine amide;Z-L-Phe-NH2;CBZ-L-PHENYLALANINE AMIDE
• CAS NO: 4801-80-3
• Molecular Formula: C₁₇H₁₈N₂O₃
• Molecular Weight: 298.34
• Mol File: 4801-80-3.mol
• Article Data: 40

Chemical Properties

• Melting Point: 165-166 °C(Solv: chloroform (67-66-3); heptane (142-82-5))
• Boiling Point: 356.9oC at 760 mmHg
• Flash Point: 169.7oC
• Appearance: /Solid
• Density: 1.143 g/cm3
• Storage Temp.: Store at RT.
• PKA: 11.13±0.46(Predicted)
• CAS DataBase Reference: Z-PHE-NH2(CAS DataBase Reference)
• NIST Chemistry Reference: Z-PHE-NH2(4801-80-3)
• EPA Substance Registry System: Z-PHE-NH2(4801-80-3)

Safety Data

• Hazardous Substances Data: 4801-80-3(Hazardous Substances Data)

Usage

General Description

Z-PHE-NH2, also known as carbobenzoxy-L-phenylalanine, is a complex organic compound commonly utilized in various scientific research, notably in medicinal chemistry and organic synthesis. It belongs to the family of phenylalanines and derivatives which are aromatic compounds containing the phenylalanine moiety. In specific contexts, this compound is used in the preparation of diverse peptide-based drugs due to its active component – the phenylalanine moiety. It is generally used as a protecting agent for the amino group during peptide synthesis, ensuring the successful conjugation of amino acids. Despite its extensive utilization in drug synthesis, there is limited information about its toxicity or potential health effects.

Upstream product

• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 501-53-1 benzyl chloroformate 
• 928406-59-1 [(S)-1-((S)-1-Amino-3-hydroxy-propylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester 
• 127-88-8 N,N-di(2-chloroethyl)amidophosphoric acid dichloride 
• 928406-72-8 [(S)-1-((R)-1-Amino-3-hydroxy-propylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester 
• 1161-13-3 N-Cbz-L-Phe 
• 541-41-3 chloroformic acid ethyl ester 
• 54769-22-1 1-methanesulfonyloxy-1,2,3-benzotriazole 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 543-27-1 isobutyl chloroformate 
• 5241-58-7 L-Phenylalanine amide 
• 39608-52-1 benzyl carbonochloridate 
• 65864-22-4 (S)-2-amino-3-phenylpropionamide hydrochloride 
• 35909-92-3 N-carbobenzoxy-L-phenylalanine methyl ester 

Downstream Products

• 5241-57-6 L-phenylalaninamide acetate salt 
• 5241-58-7 L-Phenylalanine amide 
• 52396-85-7 Z-(S)-phenylalanine thioamide 
• 91177-54-7 Z-Phe-Δ^ZPhe-OH 
• 88463-10-9 Cbz-Phe-ΔPhe-OH 
• 62076-57-7 Z-Phe-ΔAla 
• 209047-58-5 N-trityl-L-phenylalaninamide 
• 308277-53-4 (S)-2-[2-((S)-2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-2-methoxycarbonyl-acetylamino]-3-methyl-butyric acid methyl ester 
• 93661-94-0 Cbz-Phe-ΔPhe-Gly-Leu-Met-NH2 
• 133489-44-8 N-[N-(phenylmethoxy)carbonyl-L-phenylalanyl]-2-hydroxyglycine 
• 88463-18-7 (S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropionamide 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 18942-49-9 Boc-D-Phe-OH 
• 63-91-2 L-phenylalanine 

Relevant articles and documents

Synthesis of Terminal Thiazoles from N-Protected Amino Acids and a Study of Their Antibacterial Activities

-

Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P1-7

Two potent SP1-7 peptidomimetics have been successfully radiolabeled via [11C]CO2-fixation with excellent yields, purity, and molar activity. l-[11C]SP1-7-peptidomimetic exhibited promising ex vivo biodistribution profile. Metabolite analysis showed that l-[11C]SP1-7-peptidomimetic is stable in brain and spinal cord, whereas rapid metabolic degradation occurs in rat plasma. Metabolic stability can be significantly improved by substituting l-Phe for d-Phe, preserving 70% more of intact tracer and resulting in better brain and spinal cord tracer retention. Positron emission tomography (PET) scanning confirmed moderate brain (1.5 SUV; peak at 3 min) and spinal cord (1.0 SUV; peak at 10 min) uptake for l- and d-[11C]SP1-7-peptidomimetic. A slight decrease in SUV value was observed after pretreatment with natural peptide SP1-7 in spinal cord for l-[11C]SP1-7-peptidomimetic. On the contrary, blocking using cold analogues of l- and d-[11C]tracers did not reduce the tracers' brain and spinal cord exposure. In summary, PET scanning of l- and d-[11C]SP1-7-peptidomimetics confirms rapid blood-brain barrier and blood-spinal-cord barrier penetration. Therefore, further validation of these two tracers targeting SP1-7 is needed in order to define a new PET imaging target and select its most appropriate radiopharmaceutical.

Metastin derivatives and use thereof

The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing activity or cancer growth suppressing activity have been found. Furthermore, it has been found that these metastin derivatives exhibit effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc., which are wholly different from the effects heretofore known.